NCT05429502 2025-10-10
Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors
Novartis
Phase 1 Terminated
Clinical Trials
29 trialsNCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
NCT04421378 2024-12-16
A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma
Karyopharm Therapeutics Inc
Phase 1/2 Terminated
NCT04525014 2024-10-31
PIRATE
EpicentRx, Inc.
Phase 1 Terminated
NCT01127178 2024-10-10
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Terminated
NCT04324840 2024-07-26
A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma
Celgene
Phase 1 Terminated
NCT02880410 2024-04-12
FLAG
Monteris Medical
Phase 1 Terminated
NCT03495921 2023-04-26
VITA
Gradalis, Inc.
Phase 3 Terminated
NCT04851834 2022-12-20
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Xennials Therapeutics Australia Pty Ltd
Phase 1/2 Terminated
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT01587144 2021-10-19
Safety and Efficacy Study of Lucanthone When Used in Combination With Temozolomide(TMZ) and Radiation to Treat Glioblastoma Multiforme(GBM)
Spectrum Pharmaceuticals, Inc
Phase 2 Terminated
NCT03419403 2021-04-14
UNITE Study: Understanding New Interventions With GBM ThErapy
AbbVie
Phase 3 Terminated
NCT02340156 2021-03-03
Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma
SynerGene Therapeutics, Inc.
Phase 2 Terminated
NCT02414165 2020-02-07
Toca5
Tocagen Inc.
Phase 2/3 Terminated
NCT01284335 2019-01-10
A Safety Study in Participants With Advanced Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02850744 2018-10-19
Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamic Effects of PQR309 in Glioblastoma Patients
PIQUR Therapeutics AG
Phase 2 Terminated
NCT00960063 2018-08-27
A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02254954 2018-02-27
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
Actelion
Phase 1 Terminated
NCT00638963 2017-06-14
STOP
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00266812 2017-06-08
Safety and Tolerability of Low-Dose Temozolomide During Whole Brain Radiation in Patients With Cerebral Metastases From Non-Small-Cell Lung Cancer (Study P04071)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00423150 2017-06-08
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00632203 2017-06-07
Study of Maintenance Temozolomide Versus Observation in Stable or Responding Stage III/IV Non-Small Cell Lung Cancer Patients (Study P05146)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00034697 2017-05-23
Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143)
Merck Sharp & Dohme LLC
Phase 2 Terminated
NCT00811993 2016-11-02
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Terminated
NCT00724841 2016-07-22
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT00761280 2014-11-14
SAPPHIRE
Isarna Therapeutics GmbH
Phase 3 Terminated
NCT00389090 2012-02-09
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Keryx / AOI Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00615186 2011-02-10
Glass-Art
Bradmer Pharmaceuticals Inc.
Phase 3 Terminated
NCT00272415 2009-03-11
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
Genentech, Inc.
Phase 1 Terminated